Search - tctmd.com

Displaying 1 - 4 of 4

Sort: Relevancy | Date

Randomized, Double-blind, Placebo-controlled, Phase 3, Study To Evaluate Lerodalcibep Long-term Efficacy And Safety In Patients With, Or At Very-high Or High Risk, For Cardiovascular Disease On Stable Lipid-lowering Therapy

Presentation ACC 2024

Randomized, Double-blind, Placebo-controlled, Phase 3, Study To Evaluate Lerodalcibep Long-term Efficacy And Safety In Patients With, Or At Very-high Or High Risk, For Cardiovascular Disease On Stable Lipid-lowering Therapy

Presenter: Eric Quinton Klug

April 07, 2024

Comparison of an “Inclisiran First” Strategy With Usual Care in Patients With Atherosclerotic Cardiovascular Disease: Results From the VICTORION-INITIATE Randomized Trial

Presentation ACC 2024

Comparison of an “Inclisiran First” Strategy With Usual Care in Patients With Atherosclerotic Cardiovascular Disease: Results From the VICTORION-INITIATE Randomized Trial

Presenter: Michael J. Koren

April 06, 2024

Safety and Efficacy of AKCEA-APO(a)-LRx to Lower Lipoprotein(a) Levels in Patients With Established Cardiovascular Disease: A Phase 2 Dose-Ranging Trial

Presentation AHA 2018

Safety and Efficacy of AKCEA-APO(a)-LRx to Lower Lipoprotein(a) Levels in Patients With Established Cardiovascular Disease: A Phase 2 Dose-Ranging Trial

Presenter: Sotirios Tsimikas

November 11, 2018

Availability and Affordability of Cardiovascular Disease Medicines and Their Effect on Use in High-, Middle-, and Low-Income Countries

Presentation

Availability and Affordability of Cardiovascular Disease Medicines and Their Effect on Use in High-, Middle-, and Low-Income Countries

Presenter: R. Khatib

October 26, 2015

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.